Verification of the Correlation between Progression-free Survival and Overall Survival Considering Magnitudes of Survival Post-progression in the Treatment of Four Types of Cancer

Liu, Li-Ya; Yu, Hao; Bai, Jian-Ling; Zeng, Ping; Miao, Dan-Dan; Chen, Feng

추천

검색

자료유형: 학술저널

저자정보: Liu, Li-Ya (Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University) Yu, Hao (Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University) Bai, Jian-Ling (Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University) Zeng, Ping (Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University) Miao, Dan-Dan (Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University) Chen, Feng (Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제3호

발행연도: 2015.1

수록면: 1,001 - 1,006 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: With development and application of new and effective anti-cancer drugs, the median survival post-progression (SPP) is often prolonged, and the role of the median SPP on surrogacy performance should be considered. To evaluate the impact of the median SPP on the correlation between progression-free survival (PFS) and overall survival (OS), we performed simulations for treatment of four types of cancer, advanced gastric cancer (AGC), metastatic colorectal cancer (MCC), glioblastoma (GBM), and advanced non-small-cell lung cancer (ANSCLC). Materials and Methods: The effects of the median SPP on the statistical properties of OS and the correlation between PFS and OS were assessed. Further, comparisons were made between the surrogacy performance based on real data from meta-analyses and simulation results with similar scenarios. Results: The probability of a significant gain in OS and HR for OS was decreased by an increase of the SPP/OS ratio or by a decrease of observed treatment benefit for PFS. Similarly, for each of the four types of cancer, the correlation between PFS and OS was reduced as the median SPP increased from 2 to 12 months. Except for ANSCLC, for which the median SPP was equal to the true value, the simulated correlation between PFS and OS was consistent with the values derived from meta-analyses for the other three kinds of cancer. Further, for these three types of cancer, when the median SPP was controlled at a designated level (i.e., < 4 months for AGC, < 12 months for MCC, and <6 months for GBM), the correlation between PFS and OS was strong; and the power of OS reached 34.9% at the minimum. Conclusions: PFS is an acceptable surrogate endpoint for OS under the condition of controlling SPPs for AGC, MCC, and GBM at their limit levels; a similar conclusion cannot be made for ANSCLC.

#Progression-free survival #overall survival #survival post-progression #surrogate endpoint #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Liu, Li-Ya

소속기관 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University